Hims & Hers vs OrderlyMeds: November 2026 prices compared
As of November 20, 2026, from each program’s own page: on compounded tirzepatide, only OrderlyMeds prints a comparable month-to-month price, $299 a month; Hims & Hers’s page could not be read on November 20, 2026, so no like-for-like comparison is possible.
Released · Last reviewed · how we verify
On compounded semaglutide, only OrderlyMeds prints a comparable month-to-month price, $149 a month; Hims & Hers’s page could not be read on November 20, 2026, so no like-for-like comparison is possible.
Hims & Hers and OrderlyMeds, measure by measure
| Measure | Hims & Hers | OrderlyMeds |
|---|---|---|
| Tirzepatide, month to month | — | $299 (per month) |
| Tirzepatide, lowest printed | — | $149 (2-month new-customer offer, $299) |
| Semaglutide, month to month | — | $149 (per month) |
| Semaglutide, lowest printed | — | $74 (2-month new-customer offer, $149) |
| Dose pricing | not confirmed | same price at every dose |
| Membership or program fee | not confirmed | none |
| Computed score | not scored (brand route) | 27.9 of 40 (position 6 of 27) |
| FDA warning letters | 716567 (2025-09-09); 716825 (2025-09-09) | 728291 (2026-06-08) |
| November 20 read | not readable Nov 20 | first-party read |
Strengths and limitations: which fits whom
Hims & Hers suits someone who wants brand medication, FDA-approved, and accepts a higher monthly cost or has coverage. OrderlyMeds prints one price at every dose with no membership, so a dose increase does not change the bill. Compounded tirzepatide and semaglutide are not FDA-approved and are not the same products as Zepbound or Wegovy; a licensed clinician decides whether either is appropriate for you.
What changed since August
The first version of this comparison used captures from August 5–10, 2026. The November 20 re-read replaces them; the August figures are kept below as history, dated.
| Program | Medication | August 5–10, 2026 | November 20, 2026 |
|---|---|---|---|
| OrderlyMeds | tirzepatide | — | $299 |
| OrderlyMeds | semaglutide | — | $149 |
Regulatory record
FDA’s warning-letter index lists warning letter 716567 (dated September 9, 2025, subject “Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)”) and warning letter 716825 (dated September 9, 2025, subject “Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)”) to Hims & Hers; no close-out letter is listed. A warning letter is FDA’s formal notice of alleged violations, not a recall, ban or court finding. FDA’s warning-letter index lists warning letter 728291 (dated June 8, 2026, subject “False & Misleading Claims/Misbranded (Telehealth)”) to OrderlyMeds; no close-out letter is listed. A warning letter is FDA’s formal notice of alleged violations, not a recall, ban or court finding.
Frequently asked
Which is cheaper, Hims & Hers or OrderlyMeds?
On compounded tirzepatide, only OrderlyMeds prints a comparable month-to-month price, $299 a month; Hims & Hers’s page could not be read on November 20, 2026, so no like-for-like comparison is possible. On compounded semaglutide, only OrderlyMeds prints a comparable month-to-month price, $149 a month; Hims & Hers’s page could not be read on November 20, 2026, so no like-for-like comparison is possible.
Do Hims & Hers and OrderlyMeds charge a membership fee?
Hims & Hers: not confirmed on November 20, 2026; OrderlyMeds: no membership fee. This site folds any required recurring fee into the all-in figures above, so the comparison already counts it.
Are Hims & Hers and OrderlyMeds medications FDA-approved?
Compounded tirzepatide and semaglutide from any telehealth program are not FDA-approved and are not the same products as Zepbound, Mounjaro, Wegovy or Ozempic. Brand medications sold through a manufacturer or a brand route are FDA-approved. Ask each program which pharmacy fills the prescription.
Sources
- FDA: Concerns with unapproved GLP-1 drugs used for weight loss (content current as of October 1, 2026; read November 20, 2026)
- Federal Register 91 FR 23431: proposed 503B bulks-list decision for semaglutide, tirzepatide and liraglutide (May 1, 2026; no final notice found as of November 20, 2026)
- Zepbound (tirzepatide) prescribing information on DailyMed (read November 20, 2026)
- Wegovy (semaglutide) prescribing information on DailyMed (read November 20, 2026)
- Hims & Hers pricing page (not readable on November 20, 2026)
- OrderlyMeds pricing page (read November 20, 2026)
- FDA warning letter 716567 to Hims & Hers (dated 2025-09-09, posted 2025-09-16)
- FDA warning letter 716825 to Hims & Hers (dated 2025-09-09, posted 2025-09-16)
- FDA warning letter 728291 to OrderlyMeds (dated 2026-06-08, posted 2026-06-16)